APA (7th ed.) Citation

SK, P., L, A., P, T., C, S., MH, V., G, d. V., . . . TK, C. (2023). Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial. Lancet (London, England), 402(10397), 185. https://doi.org/10.1016/S0140-6736(23)00922-4

Chicago Style (17th ed.) Citation

SK, Pal, et al. "Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial." Lancet (London, England) 402, no. 10397 (2023): 185. https://doi.org/10.1016/S0140-6736(23)00922-4.

MLA (9th ed.) Citation

SK, Pal, et al. "Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial." Lancet (London, England), vol. 402, no. 10397, 2023, p. 185, https://doi.org/10.1016/S0140-6736(23)00922-4.